Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by palinc2000on Jul 13, 2022 5:10pm
259 Views
Post# 34822191

Today s Financing

Today s FinancingToday s financing has really just TWO postives IMO.
1-It pushes back the dark cloud of the darn Convert  due in less than 12 months .The Convert was an unsecured loan bearing interest at 5.75% and is being repaid by a Secured Term LOan bearing interest at more than 11% .....So more than half of the term loan is used to retire the Convert ,However only 40 million of the term loan is made available at Closing without any conditions .The balance of the term loan will ne made available in 3 tranches upon THTX achieving undisclosed milestones ,,,,,Not knowing what the milestones are its hard to say if they are easily achievable ...(based on sales %% based on stock issues?,based on cash flow ? I dontt hink that clinical results are part of the milestones

SO today the Company is getting oxigen to push back the June 30 2023 Convert darl Cloud....
I am not sure if the company will disclose the milestones which would trigger the disbursements of the tranches,,,,I expect they will after Closing 

So a sigh of relief but for now it is just a refinancing of PART of the Convert (Convert 57 million new cash at Closing 40 million)

2-The second positive is that it should be easier to attract new equity investors to fund the R&D since the company will not have  the risk of defauting on the Convert in the short term

SO I think we will see some new money rather quickly from partnerships .collaboration agreements,and possibly equity
The market will react favorably  once the NEW money comes in



<< Previous
Bullboard Posts
Next >>